Public health
Startups sell off-label longevity drugs without clinical data
12 min
Biotech firms are now marketing rapamycin and metformin for anti-aging directly to consumers despite a total lack of long-term clinical trial data for healthy adults. This examines the regulatory loophole allowing 'off-label' prescriptions to become a billion-dollar wellness industry.
Listen on the app, request early access:
Show notes
Twenty-one percent of all United States prescriptions are now written for off-label uses.
Rapamycin has extended the lifespan of mice by ten to twenty-five percent in laboratory studies.
Metformin can reduce mitochondrial adaptations to aerobic exercise by thirty to fifty percent.
Telehealth startups are bypassing decade-long clinical trials to sell unapproved aging protocols directly to consumers.
The longevity market is projected to reach a ten billion dollar valuation by twenty twenty-six.
Companies are using epigenetic clocks as biological biomarkers to bridge the gap in slow clinical data.
In this episode
- 1Intro1 min
- 2The Rise of the Longevity Telehealth Loophole2 min
- 3Rapamycin: From Organ Transplants to the Fountain of Youth3 min
- 4Metformin and the TAME Trial Standoff3 min
- 5The Regulatory Future: One Trial vs. Two2 min
- 6Outro1 min
Fylom generates episodes like this on any topic you're curious about.
Fylom episodes are researched and written by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.